Identification of Risk Factors and Predictive Indicators for Tigecycline‐Associated Hypofibrinogenemia
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70213 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Xiaohui Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Ch…. Hauptthemen laut MEDLINE: Tigecycline, Afibrinogenemia, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Hunan Province, the Science and Health Joint Project of the Natural Science Foundation of Hunan Province, the Project of Hunan Provincial Health Commission.
Abstract (Originalsprache)
To investigate the prevalence, clinical manifestations, and risk factors of hypofibrinogenemia after tigecycline use, which can disrupt coagulation and potentially hinder antimicrobial therapy. This observational study was conducted from January to December 2021 at a tertiary general hospital in China. All patients over 18 years old who received tigecycline for more than 48 h were included. After treatment with tigecycline, patients were divided into two groups based on fibrinogen plasma concentrations of less than 2.0 g/L. Multivariable logistic regression was performed to identify risk factors for hypofibrinogenemia associated with tigecycline. A total of 50 patients (mean age 71.3 ± 20.2 years) were analyzed. The median duration of treatment was 8 days (range: 3 to 20 days). Among the 24 patients who developed hypofibrinogenemia, three gastrointestinal bleeding events were observed, and four of these patients required fibrinogen administration. We identified the total therapeutic dose (odds ratio (OR) = 15.28, 95% confidence interval (CI) 2.10–111.02, p = 0.01) and a baseline direct bilirubin level greater than 0.4 mg/dL (OR = 5.79, 95% CI 1.13–27.98, p = 0.04) as risk factors for tigecycline‐induced hypofibrinogenemia. Conversely, a baseline fibrinogen level (OR = 0.53, 95% CI 0.29–0.97, p = 0.04) appeared to be a protective factor. Healthcare professionals should be aware that the administration of tigecycline may be associated with hypofibrinogenemia and severe adverse reactions. Regular monitoring of coagulation is essential, particularly for patients with liver dysfunction, low baseline fibrinogen levels, elevated baseline direct bilirubin levels, or those receiving higher total therapeutic doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, China.
- Department of Nosocomial Infection Management, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, China.
- Department of Respiratory and Critical Care Medicine, The First Hospital of Changsha(The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, China.
- Department of Pediatric, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, China.
- Department of Hematology & Oncology, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China.
ORCID-Profile: Xiaohui Liu, Jiheng Liu
Förderung
- Natural Science Foundation of Hunan Province
- the Science and Health Joint Project of the Natural Science Foundation of Hunan Province
- the Project of Hunan Provincial Health Commission
Zitieren
APA
Liu, X., Yuan, X., Wen, L., Tan, X., Sui, Q., & Liu, J. (2025). Identification of Risk Factors and Predictive Indicators for Tigecycline‐Associated Hypofibrinogenemia. Clinical and Translational Science. https://doi.org/10.1111/cts.70213
Vancouver
Liu X, Yuan X, Wen L, Tan X, Sui Q, Liu J. Identification of Risk Factors and Predictive Indicators for Tigecycline‐Associated Hypofibrinogenemia. Clinical and Translational Science. 2025. doi:10.1111/cts.70213
BibTeX
@article{Liu2025,
author = {Liu, Xiaohui and Yuan, Xuefeng and Wen, Long and Tan, Xin and Sui, Qian and Liu, Jiheng},
title = {Identification of Risk Factors and Predictive Indicators for Tigecycline‐Associated Hypofibrinogenemia},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70213}
}
EUVIMED